Validation of Japanese Bleeding Risk Criteria in Patients After Percutaneous Coronary Intervention and Comparison With Contemporary Bleeding Risk Criteria

Takeshi Shimizu, MD, PhD; Yuya Sakuma, MD; Yuta Kurosawa, MD; Yuuki Muto, MD; Akihiko Sato, MD, PhD; Satoshi Abe, MD, PhD; Tomofumi Misaka, MD, PhD; Masayoshi Okawa, MD, PhD; Akio Yoshina, MD, PhD; Takayoshi Yamaki, MD, PhD; Kazuhiko Nakazato, MD, PhD; Takaumi Ishida, MD, PhD; Yasuhiro Takeishi, MD, PhD

Background: The utility of the Japanese version of high bleeding risk (J-HBR) criteria compared with contemporary bleeding risk criteria, including Academic Research Consortium for High Bleeding Risk criteria, has not been fully investigated.

Methods and Results: This study included patients who underwent percutaneous coronary intervention between 2010 and 2019. The J-HBR score was calculated by assigning 1 point for each major criterion and 0.5 points for each minor criterion in the J-HBR criteria. Among 1,643 patients, 1,143 (69.6%) met the J-HBR criteria. Accumulated major bleeding event rates at 1 year were higher among those who met the J-HBR criteria (4.8% vs. 0.6%; P<0.001). J-HBR criteria had higher sensitivity (94.8%) and lower specificity (31.4%) than contemporary bleeding risk criteria in predicting major bleeding. Bleeding events increased with increasing J-HBR score. The C statistic for the J-HBR score for predicting major bleeding at 1 year was 0.75 (95% confidence interval 0.69–0.81), and is comparable to that of other risk scores. In multivariate analysis, of the factors included in J-HBR criteria, chronic kidney disease, heart failure, and active malignancy were associated with major bleeding.

Conclusions: J-HBR criteria identified patients at high bleeding risk with high sensitivity and low specificity. Bleeding risk was closely related to J-HBR score and its individual components. The discriminative ability of the J-HBR score was comparable to that of contemporary bleeding risk scores.

Key Words: Bleeding; Coronary artery disease; Risk stratification
ing the ARC-HBR criteria, has not been fully investigated. Therefore, in this study we validated the J-HBR criteria in a cohort of patients with coronary artery disease who were undergoing PCI, and compared the J-HBR criteria with contemporary bleeding risk criteria, including the ARC-HBR criteria, the PRECISE-DAPT score, the PARIS bleeding risk score, and the CREDO-Kyoto bleeding risk score. Furthermore, we examined the potential risk of each criterion in the J-HBR criteria for a major bleeding event.

Methods
Patient Population and Study Protocol
In all, 1,643 consecutive patients with coronary artery disease who underwent PCI at Fukushima Medical University Hospital between January 2010 and December 2019 were included in this study. Patients were divided into 2 groups, a J-HBR group and a non-HBR group, according to the definition of the J-HBR criteria. Patients were followed up until March 2021. The status and/or dates of death of patients were obtained from patients’ medical records, the attending physicians at the patients’ referring hospitals, or by contacting patients by telephone.

All patients provided written informed consent. The study protocol was approved by the Ethics Committee of Fukushima Medical University, and the study was performed in accordance with the principles outlined in the Declaration of Helsinki.

J-HBR Criteria
The J-HBR criteria included specific major criteria, such as low body weight (<55 kg for men, <50 kg for women), renal failure involving dialysis, heart failure, and peripheral vascular disease, in addition to the major and minor ARC-HBR criteria. Patients were considered to be at high bleeding risk if at least 1 major criterion or 2 minor criteria in the J-HBR criteria were met. Data for several major and minor J-HBR criteria, including history of non-traumatic bleeding event, chronic bleeding diathesis, liver cirrhosis with portal hypertension, non-deferrable major surgery on PCI, and major surgery/trauma within 30 days prior to PCI, were not available in this study, and these criteria were regarded as absent. Therefore in the present study, patients with at least 1 major criterion, such as low body weight or frailty, severe chronic kidney disease (CKD) including dialysis (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²), moderate to severe anemia (hemoglobin <11 g/dL), heart failure, anticoagulation, peripheral vessel disease, previous intracerebral hemorrhagic or severe stroke, thrombocytopenia, and active malignancy, or those with ≥2 minor criteria, such as age ≥75 years, moderate CKD (eGFR 30–59 mL/min/1.73 m²), mild anemia (hemoglobin 11–12.9 g/dL for men, 11–11.9 g/dL for women), long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) or steroids, and prior ischemic stroke not meeting the major criterion, were defined as being at high bleeding risk (i.e., J-HBR group).

Clinical Endpoint and Definitions
The primary endpoint was a bleeding event defined as Bleeding Academic Research Consortium (BARC) Type 3 or 5. The secondary endpoint was major adverse cardiovascular events (MACE), including cardiac death, non-fatal myocardial infarction, and stent thrombosis. Cardiac death was defined as any death caused by cardiac disease, procedure-related death, and sudden death of unknown cause. Myocardial infarction and stent thrombosis were defined according to the Academic Research Consortium criteria.

Comorbidities were assessed by several attending physicians using definitions reported previously. Hypertension was defined as the recent use of antihypertensive drugs, systolic blood pressure ≥140 mmHg, and/or diastolic pressure ≥90 mmHg. Diabetes was defined as the recent use of antidiabetic drugs, fasting blood glucose ≥126 mg/dL, and/or HbA1c ≥6.5%. Dyslipidemia was defined as the recent use of cholesterol-lowering drugs, triglyceride ≥150 mg/dL, low-density lipoprotein cholesterol ≥140 mg/dL, and/or high-density lipoprotein cholesterol <40 mg/dL. Heart failure was defined based on the Framingham criteria. Peripheral vascular disease was regarded as present when patients were being treated for carotid, aortic, or other peripheral vascular diseases or were scheduled for surgical or endovascular interventions. Stroke was defined as the rapid development of clinical signs of the disturbance of cerebral function lasting >24 h with imaging evidence of an acute and clinically relevant ischemic brain lesion. Severe stroke was defined as a National Institutes of Health Stroke Scale score ≥5. Intracerebral hemorrhage was defined as the rapid development of clinical signs of the disturbance of cerebral function lasting with imaging evidence of clinically relevant intracerebral bleeding. Patients were considered to have active malignancy if surgery for cancer was being planned or they were currently undergoing oncological systemic therapy and/or radiation therapy. The duration of DAPT left to the discretion of individual physicians. Unless there serious bleeding events occurred, the standard duration of DAPT was at least 1 month after bare metal stent implantation and 12 months after implantation of a drug-eluting stent, regardless of anticoagulation therapy.

Statistical Analysis
Normally distributed continuous variables are presented as the mean±SD, and were compared using Student’s t test or the Mann-Whitney U test. Categorical variables are presented as numbers and percentages, and were compared using Chi-squared tests. Kaplan-Meier cumulative event curves were constructed for bleeding events and MACE, with curves compared using the log-rank test and generalized Wilcoxon test (Gehan-Breslow). To distinguish bleeding events during the duration of DAPT, landmark analysis at 1-year was conducted. To assess the influence of the number of criteria for bleeding events and MACE, J-HBR and ARC-HBR scores were calculated by assigning 1 point for each major criterion and 0.5 points for each minor criterion in the J-HBR and ARC-HBR criteria. Cox regression models and receiver operating characteristics (ROC) curve analysis were used as measures of discrimination of the J-HBR, ARC-HBR, PRECISE-DAPT, PARIS bleeding risk, and CREDO-Kyoto bleeding risk scores to predict bleeding events at 1 year. The C statistic of the J-HBR score was compared against that of each of the other risk scores using the DeLong test, treating ROC curves as paired. Univariate and multivariate Cox proportional hazard analyses were conducted for variables in the J-HBR criteria.

Two-sided P<0.05 was considered statistically significant for all comparisons. Statistical analyses were performed using SPSS ver. 25.0 (IBM, Armonk, NY, USA).
Validation of Japanese High Bleeding Risk Criteria

The prevalence of each J-HBR criterion is shown in Figure 1. Low body weight (21.4%) and heart failure (19.6%) were the most prevalent major criteria. Moderate CKD and age >75 years were the most prevalent minor criteria.

Results

Clinical Characteristics
Comparisons of clinical characteristics between the J-HBR and non-HBR groups are presented in Table 1. Of the 1,643 patients in this study, 1,158 (70.5%) patients met the J-HBR criteria and 827 (50.3%) patients met the ARC-HBR criteria. Patients in the J-HBR group were older, were more likely to be female, had a higher prevalence of multivessel coronary artery disease, CKD, anemia, and atrial fibrillation, had a lower body mass index, were less likely to be smokers, had a lower prevalence of dyslipidemia, and lower eGFR, hemoglobin, and thrombocyte levels. The prevalence of each J-HBR criterion is shown in Figure 1. Low body weight (21.4%) and heart failure (19.6%) were the most prevalent major criteria. Moderate CKD and age >75 years were the most prevalent minor criteria.

Clinical Outcomes
During the follow-up period (mean 1,445 days), there were 97 major bleeding events and 181 MACEs. Kaplan-Meier analysis revealed that the cumulative incidence of bleeding events and MACEs was significantly higher in the J-HBR than non-HBR group (bleeding events, 4.8% vs. 0.6% at 1 year, respectively [P<0.001, log-rank test]; MACEs, 14.8% vs. 3.8% at 1 year, respectively [P<0.001, log-rank test]; Figure 2). The Gehan-Breslow Wilcoxon test revealed that the cumulative incidence of bleeding events and MACE was significantly higher in the J-HBR than non-HBR group (P<0.001 for both).

**Table 1. Clinical Characteristics of Patients Who Met the Japanese Version of High Bleeding Risk (J-HBR) Criteria and Those Who Did Not (Non-HBR)**

|                       | All patients (n=1,643) | J-HBR (n=1,158) | Non-HBR (n=485) | P value |
|-----------------------|------------------------|-----------------|-----------------|---------|
| Age (years)           | 69.3±11.5              | 71.8±11.3       | 63.3±9.6        | <0.001  |
| Male sex              | 1,291 (78.6)           | 850 (73.4)      | 441 (90.9)      | <0.001  |
| Weight (kg)           | 63.0±12.9              | 60.5±13.0       | 69.1±10.3       | <0.001  |
| Body mass index (kg/m²)| 24.2±3.7               | 23.7±3.8        | 25.4±3.2        | <0.001  |
| Smoker                | 1,056 (64.3)           | 705 (60.9)      | 351 (72.4)      | <0.001  |
| Family history        | 442 (26.9)             | 286 (24.7)      | 156 (32.2)      | 0.002   |
| Acute coronary syndrome| 833 (50.7)             | 599 (51.7)      | 234 (48.2)      | 0.198   |
| Multivessel disease   | 805 (49.0)             | 592 (51.1)      | 213 (43.9)      | 0.008   |
| Transfemoral intervention| 1,231 (74.9)       | 867 (74.9)      | 364 (75.1)      | 0.996   |
| Comorbidities         |                        |                 |                 |         |
| Hypertension          | 1,334 (81.2)           | 939 (81.1)      | 395 (81.4)      | 0.919   |
| Diabetes              | 827 (50.3)             | 595 (51.4)      | 232 (47.8)      | 0.164   |
| Dyslipidemia          | 1,323 (80.5)           | 910 (78.6)      | 413 (85.2)      | <0.001  |
| Chronic kidney disease| 736 (44.8)             | 632 (54.6)      | 104 (21.4)      | <0.001  |
| Dialysis              | 97 (5.9)               | 97 (8.4)        | 0 (0)           | <0.001  |
| Anemia                | 760 (46.3)             | 669 (57.8)      | 91 (18.8)       | <0.001  |
| Atrial fibrillation   | 249 (15.6)             | 223 (19.3)      | 26 (5.4)        | <0.001  |
| Peripheral vessel disease| 201 (12.2)             | 201 (17.4)      | 0 (0)           | <0.001  |
| Heart failure         | 322 (19.6)             | 322 (27.8)      | 0 (0)           | <0.001  |
| Previous ICH          | 14 (0.9)               | 14 (1.2)        | 0 (0)           | 0.085   |
| Previous ischemic stroke| 278 (16.9)             | 224 (19.3)      | 54 (11.1)       | <0.001  |
| Active malignancy     | 75 (4.6)               | 75 (6.5)        | 0 (0)           | <0.01   |
| Medications (at discharge) |             |                 |                 |         |
| Dual antiplatelet therapy | 1,299 (79.1)         | 850 (73.4)      | 449 (92.6)      | <0.001  |
| Anticoagulation       | 196 (11.9)             | 196 (16.9)      | 0 (0)           | <0.001  |
| NSAIDs                | 38 (2.3)               | 28 (2.4)        | 10 (2.0)        | 0.376   |
| Steroid               | 33 (2.0)               | 27 (2.3)        | 6 (1.2)         | 0.594   |
| Laboratory data       |                        |                 |                 |         |
| eGFR (mL/min/1.73m²)  | 58.8±22.7              | 53.7±23.7       | 70.9±14.2       | <0.001  |
| eGFR <30mL/min/1.73m² | 604 (36.8)             | 506 (43.7)      | 98 (20.2)       | <0.001  |
| eGFR <30mL/min/1.73m² | 167 (10.2)             | 167 (14.4)      | 0 (0)           | <0.001  |
| Hb (g/dL)             | 13.2±2.1               | 12.7±2.1        | 14.4±1.3        | <0.001  |
| 11.0≤Hb<12.9g/dL (males); | 447 (27.2)             | 385 (33.2)      | 62 (12.8)       | <0.001  |
| 11.0≤Hb<11.9g/dL (females) |             |                 |                 |         |
| Hb <11.0g/dL          | 210 (12.8)             | 210 (18.1)      | 0 (0)           | <0.001  |
| Thrombocytes (x10³/L) | 207.0±66.7             | 202.9±69.2      | 216.5±59.7      | 0.010   |
| Thrombocytes <100x10³/L| 29 (1.8)               | 29 (2.5)        | 0 (0)           | <0.001  |

Unless indicated otherwise, data are given as the mean±SD or n (%). eGFR, estimated glomerular filtration rate; Hb, hemoglobin; ICH, intracerebral hemorrhage; NSAIDs, non-steroidal anti-inflammatory drugs.
In the 1-year landmark analysis, the cumulative incidence of bleeding events was significantly higher in the J-HBR than non-HBR group both within 1 year (P < 0.001) and beyond 1 year (P = 0.021). The cumulative incidence of MACE was also significantly higher in the J-HBR than non-HBR group both within 1 year (P < 0.001) and beyond 1 year (P < 0.001; Figure 3).

With increasing J-HBR scores, there were gradual increases in the risk of bleeding events (0.6%, 2.5%, 4.6%, and 8.4% at 1 year for J-HBR scores of 0–0.5, 1–1.5, 2–2.5, and >3, respectively; P < 0.001) and MACE (3.8%, 8.8%, 11.6%, and 27.1% at 1 year for J-HBR scores of 0–0.5, 1–1.5, 2–2.5, and >3, respectively; P < 0.001; Figure 4A, B). The frequency of bleeding events was 2.5% for a J-HBR
Figure 3. Landmark analysis within and beyond 1 year. Kaplan-Meier cumulative event curves for (A) major bleeding events (Bleeding Academic Research Consortium [BARC] 3 or 5) and (B) major adverse cardiovascular events (MACE) in patients who met the Japanese version of high bleeding risk (J-HBR) criteria and those who did not (non-HBR).

Figure 4. Kaplan-Meier cumulative event curves for (A) major bleeding events (Bleeding Academic Research Consortium [BARC] 3 or 5) and (B) major adverse cardiovascular events (MACE) stratified by the Japanese version of high bleeding risk (J-HBR). (C) Major bleeding event rate at 1 year according to J-HBR scores.
score of 0, 2.3% for a score of 0.5, 4.5% for a score of 1, 6.5% for a score of 1.5, 6.2% for a score of 2, 7.9% for a score of 2.5, 9.5% for a score of 3, and 11.9% for a score >3.5 (Figure 4C).

**Comparison With Contemporary Bleeding Risk Criteria**

ROC curve analysis revealed C statistics (95% confidence intervals [CI]) for bleeding events at 1 year of 0.75 (0.69–0.81), 0.73 (0.67–0.80), 0.73 (0.67–0.80), 0.72 (0.66–0.77), and 0.73 (0.67–0.80) for the J-HBR, ARC-HBR, PRECISE-DAPT, PARIS bleeding risk, and CREDO-Kyoto bleeding risk scores, respectively (Figure 5). The cut-off values for the J-HBR, ARC-HBR, PRECISE-DAPT, PARIS bleeding risk, and CREDO-Kyoto bleeding risk scores for predicting bleeding events at 1 year were 1.75, 1.25, 29.5, 7.5, and 1.5, respectively (Figure 5). The discriminative ability of the J-HBR score was similar to that of the ARC-HBR, PRECISE-DAPT, PARIS bleeding risk, and CREDO-Kyoto bleeding risk scores (Figure 5). The sensitivity and specificity of the J-HBR, ARC-HBR, PRECISE-DAPT score ≥25, PARIS bleeding risk score ≥8, and CREDO-Kyoto bleeding risk score ≥4, which are considered as high bleeding risk in stented patients; PRECISE-DAPT, the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy.

**Table 2. Sensitivity and Specificity of Each High Bleeding Risk Score for Predicting Bleeding Academic Research Consortium 3 or 5 Bleeding Events at 1 Year**

| Score                          | Sensitivity (%) | Specificity (%) |
|-------------------------------|----------------|-----------------|
| J-HBR                         | 94.8           | 31.4            |
| ARC-HBR                       | 82.8           | 50.9            |
| PRECISE-DAPT score ≥25A       | 75.9           | 51.0            |
| PARIS bleeding risk score ≥8A | 87.9           | 54.1            |
| CREDO-Kyoto bleeding risk score ≥4A | 41.4   | 86.1            |

* These cut-off values were considered as high bleeding risk in the original reports. **ARC-HBR, Academic Research Consortium for high bleeding risk; CREDO-Kyoto, coronary revascularization demonstrating outcome study in Kyoto; J-HBR, Japanese version of high bleeding risk criteria; PARIS, patterns of non-adherence to anti-platelet regimen in stented patients; PRECISE-DAPT, the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy.
Table 3. Cox Proportional Hazard Model of Bleeding Academic Research Consortium 3 or 5 Bleeding Events

| Variables                                | Univariate analysis | Multivariate analysis |
|-------------------------------------------|---------------------|-----------------------|
| HR (95% CI)                              | P value             | HR (95% CI)           | P value             |
| Age ≥75 years                             | 1.53 (1.03–2.29)    | 0.037                 | 1.30 (0.76–2.23)    | 0.337               |
| Weight <55 kg (males), <50kg (females)   | 1.45 (0.92–2.28)    | 0.114                 | 1.25 (0.71–2.21)    | 0.448               |
| Moderate CKD (30≤eGFR<60 mL/min/1.73 m²)  | 1.77 (0.49–2.19)    | 0.247                 | 1.76 (0.87–3.53)    | 0.114               |
| Severe CKD (eGFR <30 mL/min/1.73 m²)     | 6.41 (4.15–9.90)    | <0.001                | 5.58 (2.56–12.14)   | <0.001              |
| Moderate anemia (11.0≤Hb<12.9 g/dL, males) | 1.24 (0.81–1.90)    | 0.291                 | 1.65 (0.86–3.18)    | 0.132               |
|                         (11.0≤Hb<11.9 g/dL, females) |                     |                       |                     |                     |
| Severe anemia (Hb <11.0 g/dL)            | 3.42 (2.17–5.39)    | <0.001                | 1.56 (0.75–3.25)    | 0.235               |
| Heart failure                           | 2.99 (1.98–4.51)    | <0.001                | 2.95 (1.57–5.55)    | 0.001               |
| Anticoagulation                         | 1.21 (0.67–2.16)    | 0.527                 | 1.04 (0.50–2.18)    | 0.912               |
| Peripheral vessel disease               | 1.45 (0.83–2.45)    | 0.178                 | 1.15 (0.57–2.32)    | 0.697               |
| History of ICH                          | 20.37 (0.05–50.67)  | 0.560                 | 125.5 (0.02–451.52) | 0.977               |
| Thrombocytes <100x10⁹/L                  | 0.63 (0.08–4.57)    | 0.660                 | 0.14 (0.01–163.2)   | 0.973               |
| Active malignancy                       | 3.64 (1.98–6.67)    | <0.001                | 2.90 (1.35–6.26)    | 0.007               |
| Previous ischemic stroke                | 1.38 (0.85–2.23)    | 0.195                 | 1.40 (0.70–2.80)    | 0.338               |
| NSAIDs or steroid                       | 2.87 (1.71–11.63)   | 0.140                 | 2.49 (1.60–10.31)   | 0.208               |

Cl, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HR, hazard ratio; ICH, intra-cerebral hemorrhage; NSAIDs, non-steroidal anti-inflammatory drugs.

Effects of Individual Criteria on Bleeding Events

Univariate and multivariate Cox proportional hazard analyses were conducted for variables in the J-HBR criteria (Table 3). Among the criteria, severe CKD (hazard ratio [HR] 5.58; 95% CI 2.56–12.14; P<0.001), heart failure (HR 2.95; 95% CI 1.57–5.55; P<0.001), and active malignancy (HR 2.90; 95% CI 1.35–6.26; P=0.007) were significant variables for predicting bleeding events.

Discussion

The main findings of this study are as follows. First, almost 70% of Japanese coronary artery disease patients undergoing PCI met the J-HBR criteria, and these patients were at higher risk of major bleeding events as well as MACE than patients who did not meet the J-HBR criteria. Second, an increase in the number of J-HBR criteria met was associated with an incrementally higher incidence of major bleeding events. Third, the discriminative ability of the J-HBR score for predicting 1-year major bleeding events was comparable to that of contemporary bleeding risk scores, namely the ARC-HBR, PRECISE-DAPT, PARIS bleeding risk, and CREDO-Kyoto bleeding risk scores, whereas the J-HBR score had higher sensitivity and lower specificity than the other 4 bleeding risk scores. Finally, Cox proportional hazard analysis revealed that, among the J-HBR criteria, severe CKD, heart failure, and active malignancy were significant predictors of major bleeding events. This is the first study to show the utility of the scoring approach with the J-HBR criteria for predicting major bleeding events, and to examine the discriminative ability of J-HBR relative to that of other contemporary bleeding risk scores.

The proportion of patients at high bleeding risk has been reported to be higher in the Japanese population than in Western populations. Ueki et al reported that anticoagulation, moderate and severe CKD, heart failure, acute coronary syndrome, severe anemia, severe CKD, and antiplatelet therapy were independent predictors of major bleeding in a Japanese population. In that study, severe CKD, anticoagulation, heart failure, and severe anemia had the strongest relationship with the incidence of major bleeding. Although there is some difference in the hazard risk for individual criteria in the different cohorts, it is certain that the importance of
each component in the prediction of bleeding is differs. Further investigation is required into the management of J-HBR criteria taking into consideration the hazard risk of each component for the accurate estimate of bleeding risk in patients.

Recently, several randomized trials testing shorter DAPT durations have suggested comparable antithrombotic efficacy and benefit to reduce major bleeding incidence. The GLOSEAL LEADERS trial revealed the effectiveness of 1-month DAPT with ticagrelor after PCI with a biolimus A9-eluting stent in a Western population. Among the Japanese population, the STOPDAPT-2 trial showed the safety of 1-month DAPT with clopidogrel in patients with a relatively low bleeding risk after PCI with a cobalt–chromium everolimus-eluting stent. However, the efficacy and safety of short DAPT for patients at high bleeding risk is still controversial, because almost all patients at high bleeding risk are also at high thrombotic risk, including acute coronary syndrome. The present study revealed that patients who met the J-HBR criteria had a higher risk for MACE, as well as major bleeding. The stratification of high bleeding risk may have an important role in decisions regarding the duration of DAPT for patients with high bleeding risk.

Study Limitations
This study has several limitations. First, some J-HBR criteria were not applicable, which may hinder precise estimation of bleeding risk. Second, the study was performed in a single center with a relatively small number of patients. Third, clinical practices, especially DAPT duration and PCI approach site, in the study differ to current practice. Moreover, because the information about DAPT duration was missing, the prognostic impact of DAPT duration is unclear.

Conclusions
The J-HBR criteria successfully identified patients at high bleeding risk, with high sensitivity and low specificity. The bleeding risk was closely related to J-HBR score and its individual components. The discriminative ability of the J-HBR score was comparable to that of contemporary bleeding risk scores.

Acknowledgment
The authors thank research assistant Machiko Takaba (Office for Gender Equality Support, Fukushima Medical University) for her assistance with manuscript preparation.

Sources of Funding
This study did not receive any specific funding.

Disclosures
Y.T. is a member of Circulation Journal's Editorial Team. The other authors have no conflicts of interest to declare.

IRB Information
The study protocol was approved by the Ethics Committee of Fukushima Medical University (Reference no. 823).

Data Availability
The deidentified participant data will not be shared.

References
1. Generoux P, Giustino G, Witzenbichler B, Weiss G, Stuckey TD, Rinaldi MJ, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 2013; 66: 1036–1045.
2. Costa F, van Klaveren D, James S, Heg D, Rüber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025–1036.
3. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS. J Am Coll Cardiol 2016; 67: 2224–2234.
4. Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yosihikawa Y, Shiomi H, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. J Am Heart Assoc 2018; 7: e008708.
5. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019; 140: 240–261.
6. Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, et al. Application of the Academic Research Consortium High Bleeding Risk criteria in an all-comers registry of percutaneous coronary intervention. Circ Cardiovasc Interv 2019; 12: e008307.
7. Ueki Y, Bär S, Losdat S, Otsuka T, Zanchin C, Zanchin T, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention 2020; 16: 371–379.
8. Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, et al. Validation of the Academic Research Consortium High Bleeding Risk definition in contemporary PCI patients. J Am Coll Cardiol 2020; 75: 2720–2722.
9. Corpataux N, Spinto A, Gragnano F, Vaisnora L, Galea R, Svab S, et al. Validation of high bleeding risk criteria and definition as proposed by the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2020; 41: 3743–3749.
10. Nakanura M, Iijima R. Implications and characteristics of high bleeding risk in East Asian patients undergoing percutaneous coronary intervention: Start with what is right rather than what is acceptable. J Cardiol 2021; 78: 91–98.
11. Nakanura M, Kitazono T, Kozuma K, Sekine T, Nakanura S, Shiokawa K, et al. Validation for Japanese Patients with Ischemic Heart Disease in Long-Term Clinical Practice (PRASIFT-Practice II): 1-year follow-up results of a postmarketing observational study. Circ J 2019; 84: 101–108.
12. Numasawa Y, Inohara T, Ishii H, Yamaji K, Hirano K, Kohsaka S, et al. An overview of percutaneous coronary intervention in dialysis patients: Insights from a Japanese nationwide registry. Catheter Cardiovasc Interv 2019; 94: E1–E8.
13. Numasawa Y, Kohsaka S, Ueda I, Miyata H, Sawano M, Kawamura A, et al. Incidence and predictors of bleeding complications after percutaneous coronary intervention. J Cardiol 2017; 69: 272–279.
14. Nakanura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on anti-thrombotic therapy in patients with coronary artery disease. J Cardiol 2020; 84: 831–865.
15. Natsuaki M, Morimoto T, Shiomi H, Ebara N, Taniuchi R, Tamura T, et al. Application of the modified high bleeding risk criteria for Japanese patients in an all-comers registry of percutaneous coronary intervention: From the CREDO-Kyoto Registry Cohort-III. Circ J 2021; 85: 769–781.
16. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Elekboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747.
17. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. The Academic Research Consortium-2 consensus document. Circulation 2018; 137: 2655–2650.
18. Yoshihisa A, Takiguchi M, Shimizu T, Nakanura Y, Yamauchi H, Iwaya S, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014; 64: 256–264.
19. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. *N Engl J Med* 1971; 285: 1441–1446.

20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. *Biometrics* 1988; 44: 837–845.

21. Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: The PENDULUM registry. *EuroIntervention* 2021; 19: 1154–1162.

22. Giacoppo D, Matsuda Y, Fovino LN, D’Amico G, Gargiulo G, Byrne RA, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: A systematic review and meta-analysis of randomized clinical trials. *Eur Heart J* 2021; 42: 308–319.

23. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial. *Lancet* 2018; 392: 940–949.

24. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. *JAMA* 2019; 321: 2414–2427.

25. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. *J Am Coll Cardiol* 2019; 73: 741–754.